, representing a decline of 22.1% Y-o-Y and decrease of 8.9% Q-o-Q. The Y-o-Y decrease was primarily attributed to the reduction in gross profit rate, the substantial effect of a change in foreign currency
April 1, 2018 to September 30, 2018 net profit, a decrease in full in long-term loan repayment to financial institutions by Baht 40.36 million, and a Baht 45.24 million decline in trade and other payables
of previous year of 406.89 Million Baht by subsidiaries have decline in sales of steel wires but in contrast subsidiaries distribute electricity and heat energy has increased in sale volume Revenue
beginning of the 2017 and an accrual of higher bonus payment for a better plant performance. Net Profit The Group reported a consolidated net profit of Bt672.3 million in 2Q17, representing a decline of 17.2
temporary shutdown of furnace stood at Baht 43.9 million. As a result, the Company reported net loss of Baht 30.7 million decrease from same quarter last year Bath 39.2 million. Loss per share was Baht 1.44
subsidiaries for 1Q21 at Baht 1,463 million, an increase of 32.0% from the previous quarter. When comparing to 1Q20, net profit decline slightly by 1.4%. The consolidated comprehensive income for 1Q21 totaled
Sriracha Power Plant does not caused the decrease in gross profit while the drop in revenue of IRPC-CP Phase 1 slightly decreased the gross profit. The gross profit decreased by Baht 57 million or 5% from Q2
decrease of 9.2% from 2018 and 4.4% from 2017 respectively. The Debt to Equity ratio of 0.40 times in 2019, a drop from 0.42 in 2018 and 2017, is at a level signifying reasonable capital structure and low
million, a decrease of 4% YoY, mainly due to financial statement adjustment in accordance with new Thai accounting standards and decline in overall fruit juice market. Export branded sales continued to grow
2Q 2020/21 PERFORMANCE ANALYSIS (YOY) In 2Q 2020/21, MACO recorded an operating revenue of THB 507mn, a decrease of 32.2% YoY. The decline on overall performance was from the prolonged impact of COVID